These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36643028)

  • 21. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of
    Wang T; Ishikawa T; Sasaki M; Chiba T
    Front Med (Lausanne); 2022; 9():822190. PubMed ID: 35308549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Role of gut-liver-immune axis in the pathogenesis of nonalcoholic steatohepatitis].
    Shao L; Song Y; Shi JP
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):505-509. PubMed ID: 34225424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut-Liver Axis.
    Chen X; Liu M; Tang J; Wang N; Feng Y; Ma H
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.
    Aragonès G; González-García S; Aguilar C; Richart C; Auguet T
    Biomed Res Int; 2019; 2019():8507583. PubMed ID: 30719448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enteric Pathogens and Their Toxin-Induced Disruption of the Intestinal Barrier through Alteration of Tight Junctions in Chickens.
    Awad WA; Hess C; Hess M
    Toxins (Basel); 2017 Feb; 9(2):. PubMed ID: 28208612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
    J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effect of Probiotics (MCP
    Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?
    Fukui H
    Diseases; 2019 Nov; 7(4):. PubMed ID: 31726747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review.
    Zaman CF; Sultana J; Dey P; Dutta J; Mustarin S; Tamanna N; Roy A; Bhowmick N; Khanam M; Sultana S; Chowdhury S; Khanam F; Sakibuzzaman M; Dutta P
    Cureus; 2022 Sep; 14(9):e29657. PubMed ID: 36320966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
    Chu H; Duan Y; Yang L; Schnabl B
    Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease.
    Bibbò S; Ianiro G; Dore MP; Simonelli C; Newton EE; Cammarota G
    Mediators Inflamm; 2018; 2018():9321643. PubMed ID: 29563854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The contribution of the gut-liver axis to the immune signaling pathway of NAFLD.
    Liu J; Wu A; Cai J; She ZG; Li H
    Front Immunol; 2022; 13():968799. PubMed ID: 36119048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Schisantherin A alleviates non-alcoholic fatty liver disease by restoring intestinal barrier function.
    Yu S; Jiang J; Li Q; Liu X; Wang Z; Yang L; Ding L
    Front Cell Infect Microbiol; 2022; 12():855008. PubMed ID: 36132991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.
    Ji Y; Yin Y; Sun L; Zhang W
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity, fatty liver disease and intestinal microbiota.
    Arslan N
    World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NOD2 in hepatocytes engages a liver-gut axis to protect against steatosis, fibrosis, and gut dysbiosis during fatty liver disease in mice.
    Cavallari JF; Pokrajac NT; Zlitni S; Foley KP; Henriksbo BD; Schertzer JD
    Am J Physiol Endocrinol Metab; 2020 Aug; 319(2):E305-E314. PubMed ID: 32516028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Association between intestinal flora imbalance and nonalcoholic fatty liver disease].
    Ma MJ; Wu J
    Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):789-793. PubMed ID: 29108214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.
    Wieland A; Frank DN; Harnke B; Bambha K
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1051-63. PubMed ID: 26304302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dysregulated hepatic lipid metabolism and gut microbiota associated with early-stage NAFLD in ASPP2-deficiency mice.
    Xie F; Xu HF; Zhang J; Liu XN; Kou BX; Cai MY; Wu J; Dong JL; Meng QH; Wang Y; Chen D; Zhang Y
    Front Immunol; 2022; 13():974872. PubMed ID: 36466835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endotoxins and Non-Alcoholic Fatty Liver Disease.
    Kessoku T; Kobayashi T; Imajo K; Tanaka K; Yamamoto A; Takahashi K; Kasai Y; Ozaki A; Iwaki M; Nogami A; Honda Y; Ogawa Y; Kato S; Higurashi T; Hosono K; Yoneda M; Okamoto T; Usuda H; Wada K; Kobayashi N; Saito S; Nakajima A
    Front Endocrinol (Lausanne); 2021; 12():770986. PubMed ID: 34777261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.